Aurion Biotech Announces Medical Advisory Board
SEATTLE & BOSTON & TOKYO Aurion Biotech, whose mission is to cure blindness by developing a differentiated platform of advanced therapies to treat ocular diseases, today announced the...
View Article患者安全运动基金会欢迎新任领导层
加州尔湾 (美国商业资讯)–患者安全运动基金会(PSMF)是一家全球性非营利组织,致力于在2030年前实现全球可预防的患者伤害和死亡人数清零。基金会今日宣布任命Michael A.E. Ramsay, MD, FRCA为其新任首席执行官,而Mike Durkin, OBE, MBBS, FRCA, FRCP,...
View ArticleSanBio Announces Publication Comparing Outcome Measures for Persons With...
TOKYO & MOUNTAIN VIEW, Calif. The SanBio Group (SanBio Co., Ltd. of Tokyo, Japan , SanBio, Inc. of Mountain View, California, US, and SanBio Asia Pte. Ltd. of Singapore) (TOKYO:4592), hereby...
View ArticleAsensus Surgical Announces Shinmatsudo Central General Hospital in Japan to...
RESEARCH TRIANGLE PARK, N.C. Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of...
View ArticleZAP Surgical 任命 业 内 资 深人士 领导 中国市 场 的拓展工作
加利福尼亚州圣卡洛斯市 (美国商业资讯)–ZAP-X®陀螺放射外科(Gyroscopic Radiosurgery®)平台的制造商ZAP Surgical Systems, Inc.今天宣布任命Jie Sun博士为副总裁, 负责大中华区,任命Calvin...
View ArticleZAP Surgical Appoints Industry Veterans to Lead Chinese Market Expansion
SAN CARLOS, Calif. ZAP Surgical Systems, Inc., maker of the ZAP-X® Gyroscopic Radiosurgery® platform, today announced the appointment of Jie Sun, PhD, as Vice President, Greater China, and Calvin...
View ArticlePropanc Biopharma Appoints Paul Patrizio as Strategic Advisor to Establish US...
MELBOURNE, Australia Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and...
View ArticleReValve Solutions, Inc.宣布,经中隔二尖瓣置换术首次在人体中成功运用
华盛顿州班布里奇岛 (美国商业资讯)–经导管结构性心脏置换和修复领域的创新者ReValve Solutions, Inc.今天宣布,其用于二尖瓣置换的经导管Palmetto系统首次成功完成在人体中的运用。该例重度二尖瓣反流暨心力衰竭患者的治疗获得成功。该例经股动脉-经中隔手术由Charles Davidson博士(Bluhm心血管研究所医务主任)和Edris...
View ArticleRapid Medical将启动业界首个将卒中治疗延伸至脑远端区域的试验——向新患者群体提供血栓切除术治疗
以色列约克南和迈阿密 (美国商业资讯)–先进神经血管手术器械的领先开发者Rapid Medical今天宣布,业界首个将卒中介入治疗延伸至脑远端区域的试验获得美国食品和药物管理局(FDA)在研器械豁免(IDE)批准。DISTALS研究是一项枢纽性、国际多中心随机对照试验(RCT),旨在评估远端血栓切除术的安全性和疗效。Rapid Medical开发的TIGERTRIEVER™...
View ArticleMasimo Root®搭配多模式脑监护算法或可改善老年患者的术后神经认知
瑞士纳沙泰尔 (美国商业资讯)–Masimo (NASDAQ: MASI)今天宣布了发表在《老年神经科学前沿》(Frontiers in Aging Neuroscience)上的一项前瞻性研究的结果。在该研究中,北京首都医科大学的Shuyi Yang博士及其同事对Masimo...
View Articleマルチモーダル脳モニタリングアルゴリズムを搭載したMasimo Root®は高齢患者で術後神経認知障害を改善できる可能性がある
スイス・ヌーシャテル (ビジネスワイヤ) — マシモ(NASDAQ: MASI)は本日、Frontiers in Aging Neuroscience誌に掲載された前向き試験の結果を発表しました。試験では、北京の首都医科大学のShuyi Yang医師と同僚らが、脊椎手術中の麻酔を管理するためのマルチモーダル脳モニタリングアルゴリズムを搭載したMasimo...
View ArticleNew Study Finds That Use of Masimo SedLine® PSi and DSA May Significantly...
NEUCHATEL, Switzerland Masimo (NASDAQ: MASI) today announced the findings of a prospective study published in Frontiers in Neurology in which Dr. Na Xu and colleagues at Capital Medical University...
View ArticleDEXLEVO, International Commercialization Outcomes and the “Green Light” for IPO
SEOUL, South Korea DEXLEVO achieved a sales of 30 billion dollars after CE certification for liquid polymer fillers for the first time in the world. The company is expected to obtain a license in...
View Article新研究发现,Masimo SedLine® PSi和DSA联用或可显著减少术后谵妄
瑞士纳沙泰尔 (美国商业资讯)–Masimo (NASDAQ: MASI)今天发布《神经内科前沿》(Frontiers in Neurology)上发表的一项前瞻性研究的结果。在该研究中,北京首都医科大学Na Xu博士及其同事对Root®平台上Masimo...
View Articleマシモ製のSedLine® PSiとDSAの使用により術後せん妄を大幅に低減し得ることが新たな研究で判明
スイス・ヌーシャテル (ビジネスワイヤ) — マシモ(NASDAQ: MASI)は本日、Frontiers in Neurology誌に掲載された前向き研究の知見を発表しました。本研究では、北京の首都医科大学のDr. Na Xuと同僚らが、Root®に搭載されたMasimo...
View Article中智全球和Milestone手术中心宣布使用“信任即技术”改善患者转归并加快创收
德克萨斯州弗劳尔芒德和科罗拉多州帕克 SEC³URE Ethos、SEC³URE Passport、Link&GO!、BioBytes™和BioBytes™Visitor背后的创新企业中智全球(IntelliCentrics, 6819.HK)宣布,由医生所有的女性专科门诊手术中心Milestone手术中心选择了基于信任的超大医疗技术社区SEC³URE...
View ArticleCanon Medical Signals Its Support for a Multicenter Ultrasound Liver...
OTAWARA, Tochigi Prefecture, Japan Canon Medical announced today its support for the iLEAD (innovative Liver, Elasticity, Attenuation and Dispersion) study, an international multicenter study aiming...
View ArticleDEXLEVO’s Liquid Polymer Filler Raises KRW 26 Billion in Pre-IPO Funding
SEOUL, South Korea DEXLEVO has completed its pre-IPO funding of KRW 26 billion. It thus increased its valuation by six times compared to the Series B funding in 2018 thanks to its commercialization...
View ArticleTakeda Announces Publication of Data from SOLSTICE, a Pivotal Phase 3 Trial...
OSAKA, Japan & CAMBRIDGE, Mass. Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the data from the pivotal Phase 3 SOLSTICE clinical trial of LIVTENCITY™...
View Article